Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posoleucel for Prevention of Multi-Virus Infections Post-HCT
NCT05305040Phase 3Terminated
- Sponsor
- AlloVir
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Native Immune Cells
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in adenovirus infection, BK virus infection, cytomegalovirus infection (CMV) and 3 more comparing Posoleucel with Placebo (2 arms). Primary endpoint: Average Number of Clinically Significant Infections or Episodes of End-Organ Disease Through Week 14. Started Mar 2022; status: terminated.
02
Drugs
posoleucel
03
Conditions
adenovirus infectionBK virus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infectionhuman herpesvirus 6 infection
Beyond the preview
Go deeper on NCT05305040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305040.